Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ARO-MMP7 · 1 trial · 1 indication
An adverse event (AE) was defined as any untoward medical occurrence that develops or worsens in severity during the conduct of a clinical study and does not necessarily have a causal relationship to study drug. TEAEs were defined as AEs with onset after administration of the study drug, or when a pre-existing medical condition increases in severity or frequency after study drug administration. A summary of all Serious Adverse Events (SAEs) and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.
| Arm | Type | Description |
|---|---|---|
| ARO-MMP7 | EXPERIMENTAL | single or multiple doses of ARO-MMP7 by inhalation of nebulized solution |
| Placebo | PLACEBO_COMPARATOR | single or multiple doses of placebo by inhalation of nebulized solution |
| Name | Type | Description |
|---|---|---|
| ARO-MMP7 Inhalation Solution | DRUG | ARO-MMP7 by inhalation of nebulized solution |
| Placebo | DRUG | Calculated volume of normal saline (0.9% NaCl) to match active treatment by inhalation of nebulized solution |
Inclusion Criteria (NHVs): * Normal pulmonary function tests at Screening * Normal electrocardiogram (ECG) at Screening * Non-smoking * Female participants cannot be pregnant or lactating * Male and female participants of childbearing potential must agree to use highly effective contraception and m...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Bristol-Myers Squibb Company | BMY | 2 | PHASE3 | BMS-986278 |
| United Therapeutics Corporation | UTHR | 2 | PHASE3 | Treprostinil |
| AbbVie, Inc. | ABBV | 2 | PHASE2 | ABBV-142 |
| PureTech Health PLC Sponsored ADR | PRTC | 2 | PHASE3 | Deupirfenidone, Pirfenidone |
| Syndax Pharmaceuticals Inc | SNDX | 1 | PHASE2 | Axatilimab |
| Contineum Therapeutics, Inc. Class A | CTNM | 1 | PHASE2 | PIPE-791 Dose A, PIPE-791 Dose B |
| Rein Therapeutics, Inc | RNTX | 1 | PHASE2 | LTI-03 |
| Sunshine Biopharma Incorporated | SBFM | 2 | PHASE3 | HEC585, Pirfenidone |
| Cumberland Pharmaceuticals Inc. | CPIX | 1 | PHASE2 | Ifetroban |
| Avalyn Pharma Inc | AVLN | 3 | PHASE2 | AP01 |
ARO-MMP7 is an investigational drug being developed for the treatment of idiopathic pulmonary fibrosis (IPF), a chronic and progressive lung disease. It is administered as an inhalation solution and is currently in Phase 1 clinical development.
ARO-MMP7 is being developed by Arrowhead Pharmaceuticals, Inc., a biopharmaceutical company. Arrowhead's stock is traded under the ticker symbol ARWR on the NASDAQ.
ARO-MMP7 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. A Phase 1 study has been completed, and the drug remains under investigation for idiopathic pulmonary fibrosis.
ARO-MMP7 has one completed Phase 1 clinical trial, identified as NCT05537025. This study, titled 'Study of ARO-MMP7 Inhalation Solution in Healthy Participants and Participants With Idiopathic Pulmonary Fibrosis,' enrolled 105 participants and was conducted in Denmark, Italy, New Zealand, South Korea, Spain, and the United Kingdom.
Yes, ARO-MMP7 is classified as a small molecule therapeutic. It is formulated as an inhalation solution for delivery to the lungs and is being studied for the treatment of idiopathic pulmonary fibrosis.